Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Trial Profile

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 20 Apr 2016 Results assessing potential clinical biomarkers that correlated with venetoclax sensitivity presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Dec 2014 Interim results in 32 patients presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top